Celyad's novel CAR T-cell therapy for solid malignancies - 10/05/18
Doi : 10.1016/j.retram.2018.03.001
Caroline Lonez a, Alain Hendlisz b, Leila Shaza b, Philippe Aftimos b, Michaël Vouche c, Vincent Donckier b, Jean-Pascal H. Machiels d, Marc Van Den Eynde d, Jean-Luc Canon e, Javier Carrasco e, Kunle Odunsi f, Solmaz Sahebjam g, Sylvie Rottey h, Nathalie Braun a, Bikash Verma i, David E. Gilham a, Frédéric F. Lehmann a, ⁎ 
a Celyad, Mont-Saint-Guibert, Belgium
b Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
c Department of Radiology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
d Institut Roi Albert II, Service d’Oncologie Médicale, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (Pole MIRO), Université Catholique de Louvain, Belgium
e Service d’Oncologie-Hématologie, Site Notre-Dame, Grand Hôpital de Charleroi (GHdC), Belgium
f Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States
g H Lee Moffitt Cancer Center and Research Inst, Tampa, FL, United States
h Ghent University Hospital, Ghent, Belgium
i Celyad, New York, NY, United States
⁎Corresponding author at: Celyad SA, Rue Edouard Belin 2, 1435 Mont-Saint-Guibert, Belgium.Celyad SARue Edouard Belin 2Mont-Saint-Guibert1435Belgium
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
| pagine | 4 |
| Iconografia | 2 |
| Video | 0 |
| Altro | 0 |
Abstract |
Celyad recently initiated several clinical trials with the CYAD-01 product, a natural killer group 2D (NKG2D)-based chimeric antigen receptor (CAR), in both solid and hematologic tumor types. This review discusses the unique properties of CYAD-01, expecting to provide a new paradigm to fight against solid tumors.
Il testo completo di questo articolo è disponibile in PDF.Mappa
© 2018
Elsevier Masson SAS. Tutti i diritti riservati.
Vol 66 - N° 2
P. 53-56 - maggio 2018 Ritorno al numero
Articolo precedente
- Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy
- Jordan Gauthier, Cameron J. Turtle
- Clinical units to set up chimeric antigen receptor T-cell therapy (CAR T-cells): Based on the recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)
- Ibrahim Yakoub-Agha
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?